drugset / Trial / NCT00461773
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the objective response rate of a combination of letrozole (Femara) and bevacizumab (Avastin) given preoperatively to postmenopausal patients with hormone sensitive breast cancer.
Timeline
- Start
- 2007-03
- Primary completion
- 2010-05
- Completion
- 2010-05
Outcome
Outcome not reported
Stopped: “Lack of recrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Comparator | Letrozole | Other / unclassified | 2.5 mg | Oral |